Breaking Talarico Challenges Paxton in Texas Senate Race, Highlighting Scandals and Child Abuse Case Bill Oddie, Comedian and Wildlife Presenter, Dies at 85 New Streaming Releases and Entertainment Highlights This Week Global Markets React to Shifting Geopolitics and Tech IPO Surge Former South Korean President Yoon Suk Yeol Convicted of False Statements, Receives Suspended Sentence
Monday July 27, 2026
79° Chicago, IL Fog/Mist
Become a Contributor
Section

Trending

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
Press Release

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage

Eikon Therapeutics, Inc. · 7 minutes ago
Read Full Story